[{"orgOrder":0,"company":"Amarna Therapeutics","sponsor":"NorthX Biologics","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"NETHERLANDS","productType":"Cell and Gene therapy","year":"2024","type":"Partnership","leadProduct":"Nimvec AM510","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Amarna Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amarna Therapeutics \/ NorthX Biologics","highestDevelopmentStatusID":"4","companyTruncated":"Amarna Therapeutics \/ NorthX Biologics"},{"orgOrder":0,"company":"Amarna Therapeutics","sponsor":"C4 holding BV","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Cell and Gene therapy","year":"2021","type":"Financing","leadProduct":"AMA005","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Amarna Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amarna Therapeutics \/ C4 holding BV","highestDevelopmentStatusID":"5","companyTruncated":"Amarna Therapeutics \/ C4 holding BV"},{"orgOrder":0,"company":"Amarna Therapeutics","sponsor":"Eurostars","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"NETHERLANDS","productType":"Undisclosed","year":"2024","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Discovery Platform","graph3":"Amarna Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amarna Therapeutics \/ Eurostars","highestDevelopmentStatusID":"3","companyTruncated":"Amarna Therapeutics \/ Eurostars"}]

Find Clinical Drug Pipeline Developments & Deals by Amarna Therapeutics

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          IMCAS Asia
                          Not Confirmed
                          IMCAS Asia
                          Not Confirmed

                          Details : Eurostars' funding will support their collaboration to validate Amarna's patented gene therapy platform using a novel and advanced cellular disease model for Dry AMD.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          November 12, 2024

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Discovery Platform

                          Sponsor : Eurostars

                          Deal Size : Undisclosed

                          Deal Type : Funding

                          blank

                          02

                          IMCAS Asia
                          Not Confirmed
                          IMCAS Asia
                          Not Confirmed

                          Details : The partnership focuses on advancing the clinical trial manufacturing of Nimvec AM510, Amarna’s groundbreaking gene therapy platform designed to transform the treatment of type 1 diabetes.

                          Product Name : Nimvec AM510

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          March 12, 2024

                          Lead Product(s) : Nimvec AM510

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Preclinical

                          Sponsor : NorthX Biologics

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank

                          03

                          IMCAS Asia
                          Not Confirmed
                          IMCAS Asia
                          Not Confirmed

                          Details : The funds will enable Amarna to advance its lead gene therapy AMA005, for the treatment of hemophilia B towards a first-in-human clinical trial, and to progress its R&D pipeline in selected autoimmune diseases and chronic inflammation.

                          Product Name : AMA005

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          January 12, 2021

                          Lead Product(s) : AMA005

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : IND Enabling

                          Sponsor : C4 holding BV

                          Deal Size : $5.7 million

                          Deal Type : Financing

                          blank